Chongqing Zhifei Biological Products, has stocked up more Gardasil than it can sell. As a result, Merck will stop shipping Gardasil to Zhifei at least until the middle of the year.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

Plus, the shipping pause could bring down Gardasil ... could arise from losing the exclusivity license of its other drug, Keytruda. The cancer therapy drug is one of Merck’s hero products ...

plus Keytruda (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID ...

The shipping pause will allow for a "more rapid ... Merck's efforts to offset losses from its top-selling cancer therapy Keytruda, which will lose exclusivity in 2028. Merck is hoping that ...